Skip to main content

Table 2 Distribution of EQ-5D, EORTC QLQ-C30 and EORTC QLQ-MY20 scores

From: Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma

  No. of patients Mean ± SD Median Interquartile range
EQ-5D 154 0.7 ± 0.3 0.73 0.62–1.00
EORTC QLQ-C30
  Global health status/QoL 154 60.1 ± 25.5 58.3 41.7–83.3
  Functional scales  
    Physical 154 68.7 ± 27.2 73.3 53.3–93.3
    Role 153 62.9 ± 34.6 66.7 33.3–100.0
    Emotional 154 78.1 ± 24.6 83.3 66.7–100.0
    Cognitive 154 81.4 ± 22.9 83.3 66.7–100.0
    Social 154 63.9 ± 32.9 66.7 33.3–100.0
  Symptom scales     
    Fatigue 154 38.6 ± 29.8 33.3 11.1–66.7
    Nausea/Vomiting 154 5.2 ± 11.8 0.0 0.0–0.0
    Pain 154 32.3 ± 33.4 16.7 0.0–66.7
  Single items  
    Dyspnea 154 21.9 ± 30.6 0.0 0.0–33.3
    Insomnia 154 25.1 ± 29.8 16.7 0.0–33.3
    Appetite Loss 154 15.4 ± 27.0 0.0 0.0–33.3
    Constipation 154 17.7 ± 28.6 0.0 0.0–33.3
    Diarrhea 154 8.4 ± 21.7 0.0 0.0–0.0
    Financial difficulties 154 18.4 ± 31.2 0.0 0.0–33.3
EORTC QLQ-MY20
  Disease symptoms 154 23.3 ± 22.3 16.7 0.0–38.9
  Side-effects of treatment 154 19.5 ± 17.1 14.8 7.4–29.6
  Future perspective 154 59.9 ± 28.1 66.7 33.3–77.8
  Body image 154 77.9 ± 30.5 100.0 66.7–100.0
  1. SD standard deviation.